- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT01678677
A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Non-typeable Haemophilus Influenzae (NTHi) Investigational Vaccine (GSK2838497A) in Current and Former Smokers
12. Mai 2017 aktualisiert von: GlaxoSmithKline
An Observer-blind Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Non-typeable Haemophilus Influenzae (NTHi) Investigational Vaccine (GSK2838497A) in Current and Former Smokers
The purpose of this study is to assess the safety, reactogenicity and immunogenicity of 8 different formulations of investigational NTHI vaccine in current and former smokers, 50-70 years of age.
Studienübersicht
Status
Abgeschlossen
Bedingungen
Intervention / Behandlung
- Biologisch: NTHI vaccine GSK2838500A (formulation 1)
- Biologisch: NTHI vaccine GSK2838501A (formulation 2)
- Biologisch: NTHI vaccine GSK2838502A (formulation 3)
- Biologisch: NTHI vaccine GSK2838503A (formulation 4)
- Biologisch: NTHI vaccine GSK2838504A (formulation 5)
- Biologisch: NTHI vaccine GSK2838505A (formulation 6)
- Biologisch: NTHI vaccine GSK2838508A (formulation 7)
- Biologisch: NTHI vaccine GSK2838509A (formulation 8)
- Arzneimittel: Placebo comparator
Detaillierte Beschreibung
This Protocol Posting has been updated following Protocol Amendment 1, dated 10 October 2012, leading to a change in an inclusion criterion.
Studientyp
Interventionell
Einschreibung (Tatsächlich)
272
Phase
- Phase 1
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienorte
-
-
-
Antwerpen, Belgien, 2060
- GSK Investigational Site
-
Gent, Belgien, 9000
- GSK Investigational Site
-
Wilrijk, Belgien, 2610
- GSK Investigational Site
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
50 Jahre bis 70 Jahre (Erwachsene, Älterer Erwachsener)
Akzeptiert gesunde Freiwillige
Ja
Studienberechtigte Geschlechter
Alle
Beschreibung
Inclusion Criteria:
- Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
- A male or female between, and including, 50 and 70 years of age at the time of the first vaccination.
- Written informed consent obtained from the subject.
- Subjects without medical history, clinical finding or laboratory finding which in the opinion of the investigator could pose a safety concern or interfere with the protocol.
- Current or former smokers.
- A smoking history of at least 10 pack-years.
- Female subjects of non-childbearing potential may be enrolled in the study.
Female subjects of childbearing potential may be enrolled in the study, if the subject:
- has practiced adequate contraception for 30 days prior to vaccination, and
- has a negative pregnancy test on the day of vaccination, and
- has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series.
Exclusion Criteria:
- Use of any investigational or non-registered product other than the study vaccines within 30 days preceding the first dose of study vaccine, or planned use during the study period.
- Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product.
- Planned administration/ administration of a vaccine not foreseen by the study protocol in the period starting 30 days before the first dose and ending 30 days after the last dose of vaccine, with the exception of any influenza vaccine which may be administered ≥ 15 days preceding or following any study vaccine dose.
- Previous vaccination with any vaccine containing NTHi-antigens.
- Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose. Topical steroids are allowed.
- Administration of immunoglobulins and/or any blood products within the 3 months preceding the first dose of study vaccine or planned administration during the study period.
- Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
- History of or current autoimmune disease.
- Post-bronchodilator Forced Expiratory Volume in 1 second (FEV1) < 80% of predicted normal value.
- Diagnosed with a respiratory disorder. Please note that subjects with mild pulmonary obstruction can be enrolled.
- Laboratory evidence of clinically significant haematological abnormalities at Screening.
- Acute disease and/or fever at the time of enrolment.
- Current alcoholism and/or drug abuse.
- Has significant disease, in the opinion of the investigator, likely to interfere with the study and/or likely to cause death within the study duration.
- History of or current condition preventing intramuscular injection as bleeding or coagulation disorder.
- Has contraindication for spirometry testing.
- Malignancies within previous 5 years and lymphoproliferative disorders.
- Pregnant or lactating female.
- Female planning to become pregnant or planning to discontinue contraceptive precautions.
- Any other condition that the investigator judges may interfere with study findings.
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Verdreifachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Group A
Subjects in this group will receive formulation 1 of NTHi vaccine.
|
Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
|
Experimental: Group B
Subjects in this group will receive formulation 2 of NTHi vaccine.
|
Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
|
Experimental: Group C
Subjects in this group will receive formulation 3 of NTHi vaccine.
|
Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
|
Experimental: Group D
Subjects in this group will receive formulation 4 of NTHi vaccine.
|
Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
|
Experimental: Group E
Subjects in this group will receive formulation 5 of NTHi vaccine and a placebo.
|
Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
|
Experimental: Group F
Subjects in this group will receive formulation 6 of NTHi vaccine and a placebo.
|
Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
|
Experimental: Group G
Subjects in this group will receive formulation 7 of NTHi vaccine and a placebo.
|
Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
|
Experimental: Group H
Subjects in this group will receive formulation 8 of NTHi vaccine and a placebo.
|
Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
|
Placebo-Komparator: Group Placebo 1
Subjects in this group will receive placebo.
|
Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
|
Placebo-Komparator: Group Placebo 2
Subjects in this group will receive placebo.
|
Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
Occurrence of each solicited local and general adverse event (AE), in all subjects, in all groups.
Zeitfenster: During a 7-day follow-up period (from day 0 to day 6) after each vaccination.
|
During a 7-day follow-up period (from day 0 to day 6) after each vaccination.
|
Occurrence of any unsolicited AE, in all subjects, in all groups.
Zeitfenster: During a 30-day follow-up period (from day 0 to day 29) after each vaccination.
|
During a 30-day follow-up period (from day 0 to day 29) after each vaccination.
|
Occurrence of haematological and biochemical laboratory abnormalities, in all subjects, in all groups.
Zeitfenster: Prior to each vaccination.
|
Prior to each vaccination.
|
Occurrence of haematological and biochemical laboratory abnormalities, in all subjects, in all groups.
Zeitfenster: 7 days after each vaccination.
|
7 days after each vaccination.
|
Occurrence of haematological and biochemical laboratory abnormalities, in all subjects, in all groups.
Zeitfenster: At study conclusion (Day 420).
|
At study conclusion (Day 420).
|
Occurrence of any serious adverse event (SAE), in all subjects, in all groups.
Zeitfenster: From first vaccination (Day 0) to study conclusion (Day 420).
|
From first vaccination (Day 0) to study conclusion (Day 420).
|
Occurrence of any potential immune-mediated disease (pIMD) in all subjects, in all groups.
Zeitfenster: From first vaccination (Day 0) to study conclusion (Day 420).
|
From first vaccination (Day 0) to study conclusion (Day 420).
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
Humoral immune response to the components of the NTHi vaccine formulations, in all subjects, in all groups, in terms of antibody concentrations.
Zeitfenster: Prior to each vaccination, 30 days after each vaccination, and at study conclusion (Day 420).
|
Prior to each vaccination, 30 days after each vaccination, and at study conclusion (Day 420).
|
Cell-mediated immune (CMI) responses to components of the NTHi vaccine formulations, in a sub-cohort of subjects, in all groups.
Zeitfenster: Prior to each vaccination, 30 days after each vaccination, and at study conclusion (Day 420).
|
Prior to each vaccination, 30 days after each vaccination, and at study conclusion (Day 420).
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Sponsor
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn (Tatsächlich)
31. August 2012
Primärer Abschluss (Tatsächlich)
30. Januar 2014
Studienabschluss (Tatsächlich)
30. Januar 2014
Studienanmeldedaten
Zuerst eingereicht
23. August 2012
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
30. August 2012
Zuerst gepostet (Schätzen)
5. September 2012
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
15. Mai 2017
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
12. Mai 2017
Zuletzt verifiziert
1. Mai 2017
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 116647
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Atemwegserkrankungen
-
NovavaxAbgeschlossen
-
PfizerAbgeschlossenRespiratory-Syncytial-VirenBelgien
-
NovavaxAbgeschlossenRespiratory Synctial VirusKanada
-
Janssen Vaccines & Prevention B.V.AbgeschlossenRespiratory-Syncytial-Virus-PräventionVereinigte Staaten
-
NovavaxAbgeschlossenRespiratory-Syncytial-Virus (RSV)Vereinigte Staaten
-
MedImmune LLCAbgeschlossenRespiratory-Syncytial-Virus (RSV)Vereinigte Staaten
-
AbbVieAbgeschlossen
-
University of RochesterAktiv, nicht rekrutierendRespiratory-Syncytial-Virus (RSV)Vereinigte Staaten
-
University of OxfordInnovative Medicines Initiative; Respiratory syncytial virus consortium in EuropeAktiv, nicht rekrutierendRespiratory-Syncytial-Virus (RSV)Vereinigtes Königreich
-
Enanta Pharmaceuticals, IncAbgeschlossenRespiratory-Syncytial-Virus (RSV)Vereinigte Staaten
Klinische Studien zur NTHI vaccine GSK2838500A (formulation 1)
-
Sanofi Pasteur, a Sanofi CompanyGlaxoSmithKlineAktiv, nicht rekrutierendCOVID-19Honduras, Vereinigte Staaten, Australien, Frankreich, Kenia, Mexiko, Neuseeland, Panama, Spanien, Vereinigtes Königreich
-
Sucampo Pharma Americas, LLCTakedaAbgeschlossenGesunde FreiwilligeVereinigte Staaten